Cormorant Asset Management’s Vaxcyte PCVX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCVX
Cormorant Asset Management's PCVX Position: Q3 2026 in Review
Cormorant Asset Management reduced its Vaxcyte (PCVX) stake by 70% in Q3 2026, selling an estimated $2.04M and leaving 15,000 shares worth $854K. The position accounts for 0.06% of the portfolio, ranked #59.
Cormorant Asset Management first reported a position in PCVX in Q4 2022 and has held it in 16 quarters since. The position peaked at $114M in Q3 2024. 356 funds tracked by Wall St. Rank hold PCVX as of Q3 2026.
- Cormorant Asset Management held 15,000 shares of Vaxcyte worth $854K as of Q3 2026.
- Cormorant Asset Management sold 35,000 Vaxcyte shares in Q3 2026, an estimated $2.04M.
- Vaxcyte made up 0.06% of Cormorant Asset Management's portfolio in Q3 2026, its #59 holding.
- Cormorant Asset Management first reported a position in Vaxcyte in Q4 2022 and has held it in 16 quarters since.
- Cormorant Asset Management's Vaxcyte position peaked at $114M in Q3 2024.
- 356 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2026.
Based on Cormorant Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.